UK Looks To Model New Medtech Strategy On US Successes
The UK medtech industry sees the US very much as both a vital market and learning ground for future business and health-care system successes. That was the tone at recent meetings involving the UK industry association, which is ramping up its US-facing activity.
You may also be interested in...
The UK medtech industry is in a state of flux given the known unknowns of Brexit, perennial health-care funding pressures that will only exacerbate, and a menu of cost-saving initiatives that require medtech companies to adjust how they work with the National Health Service. Improving NHS and its role as a boon to smaller UK medtech companies is an important priority of industry.
UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.
As night turned to day on June 24, it became clearer by the hour that the unthinkable had happened, and the UK’s long and acrimonious debate about its 43-year membership of the European Union had ended in a victory for the Leave group. The local health care products industries made their views clear some weeks ago, but today and in the months to come, they will have to confront a Plan B that was never in the plans.